Missed a Zepbound dose?

The entire missed-dose rule for Zepbound hinges on one number: 96 hours, which is the same as 4 full days. If you catch the miss within that window — whether it's two hours after your usual injection time or three and a half days later — the instruction is simple: take the dose as soon as you remember it, then continue your regular weekly schedule from your original day going forward. There's no partial dose, no adjustment, no need to shift your entire week around it.

Once you're past the 96-hour mark, the guidance flips. You do not take the missed dose late, and you do not take it alongside your next scheduled dose. You skip it outright and wait for your next regularly scheduled injection day, taking that dose as normal. This might feel counterintuitive — skipping a dose seems like it should be the last resort — but it's the label-supported approach precisely because tirzepatide is dosed weekly with a long half-life, and cramming a late dose in too close to the next one creates more risk than it solves.

If you genuinely aren't sure how many hours have passed — say, you know it's been "a few days" but didn't note the exact time — treat it conservatively. Estimate on the high side, and if there's real ambiguity about whether you're inside or outside the 96-hour window, it's reasonable to call your pharmacist or prescriber's office and ask rather than guess. The downside of guessing wrong in either direction (taking a too-late dose, or skipping one you didn't need to) is small for a single dose, but there's no reason to guess when a five-minute phone call resolves it.

The second half of the label rule is just as important as the 96-hour catch-up window, and it's the part people most often overlook: no matter why you're adjusting your schedule, two Zepbound doses can never be closer together than 3 days, or 72 hours. This applies whether you're catching up on a late dose, deliberately shifting your injection day for a trip, or anything else — the 72-hour floor is absolute.

Here's where this actually shows up in practice. Say your regular injection day is Monday, and you miss it. You remember on Wednesday — about 48 hours late, well inside the 96-hour window — so you take it Wednesday. Your next dose is technically supposed to be "next Monday," but Monday is only 5 days after this Wednesday's catch-up dose, which is fine, since 5 days clears the 72-hour minimum with room to spare. But if you'd caught the miss even later — say, Friday, 4 days after the original Monday — taking it Friday and then trying to return to Monday would only leave 3 days of gap, right at the edge of the minimum. In tighter cases like this, it's common for the regular schedule to shift by a day or two rather than snapping back to the original day immediately.

The practical takeaway: after any catch-up dose, don't assume your next injection date is "whatever day it was originally." Count forward from the day you actually took the catch-up dose, confirm at least 72 hours will separate it from your next planned dose, and adjust your regular day forward if needed. Once you've re-established a comfortable gap, you can either keep the new day going forward or shift back toward your original day over a week or two, as long as you never compress two doses inside that 72-hour floor while doing so.

This rule exists for a straightforward pharmacological reason: tirzepatide is designed around a once-weekly exposure curve, and stacking two doses too close together pushes drug concentration higher than the label's studied dosing intervals ever tested. The 72-hour minimum isn't an arbitrary scheduling convenience — it's the floor below which the label doesn't have safety and efficacy data to stand on, which is exactly why it's stated as a hard minimum rather than a suggestion.

The instinct to double up — take the missed dose and the next scheduled one close together, or even at the same time — is common and understandable. It feels like it should even things out. It doesn't, and the label explicitly does not support this approach. Zepbound's dosing was studied at fixed weekly intervals; there's no clinical trial data showing what happens, safety-wise or efficacy-wise, when you push two full doses into a shorter window than that. "It should be fine" is a guess, not a label-backed instruction.

The more concrete downside is gastrointestinal. Tirzepatide's most common side effects — nausea, vomiting, diarrhea, constipation — are dose- and concentration-dependent, meaning they tend to track with how much drug is active in your system at a given time. Two doses compressed close together means a higher peak concentration than your body has been adjusted to, which is exactly the scenario most likely to trigger a rough GI episode, especially if you're still in the earlier steps of titration where tolerance hasn't fully built up yet.

There's also no offsetting benefit to doubling up. Skipping a single dose and resuming your regular schedule doesn't meaningfully change your long-term trajectory — one week's gap gets absorbed into months of ongoing weekly treatment. Doubling up doesn't "catch you up" faster in any way the data supports; it just adds risk for no measurable gain. The skip-and-resume path is the boring option, and boring is exactly what you want here.

A missed dose carries a slightly different weight depending on where you are in treatment. If you're on a stable maintenance dose you've been taking for months, a single late or skipped dose is a minor blip — your body has already adjusted to that concentration, and one week's gap doesn't meaningfully change your GI tolerance or how the next dose feels. If you're still actively titrating — working your way up through the early dose steps — the calculus is a bit different.

Titration exists specifically to let your body build tolerance gradually before the dose increases again. That built-up tolerance is partly a function of consistent, regular exposure at your current step. A missed dose that falls within the standard 96-hour catch-up window doesn't disrupt this much — you're still getting your weekly exposure on roughly schedule. But a longer gap, even one that technically follows the skip-and-resume rule, can mean going 10, 11, or more days without any tirzepatide in your system, which starts to erode the tolerance you'd built at that dose.

This matters most right around a planned dose increase. If you missed a dose and then your next scheduled injection happens to be a step-up day, arriving at that day with less built-up tolerance than usual — because of the extended gap — is worth flagging to your prescriber before you increase. Some prescribers will recommend repeating your current dose one more week before stepping up, rather than titrating up on schedule as if the gap hadn't happened. This isn't a formal label rule; it's a clinical judgment call based on how your body responds, which is exactly why it belongs in a conversation with whoever is managing your titration schedule rather than something to decide alone.

The general principle worth internalizing: titration is about gradual, consistent exposure building comfort with each step before the next one. Anything that breaks the "gradual and consistent" part — a longer-than-usual gap, a missed step, an extended pause for any reason — is worth treating as a reason to pause and check in, not just push forward on the pre-set schedule as though nothing happened.

Everything above assumes a single missed dose. Missing two or more consecutive weekly doses is a materially different situation, and it's the point where self-managing with the standard catch-up rule stops being the right approach. Two missed doses in a row means somewhere around two to three weeks without tirzepatide in your system — long enough that the drug has likely cleared well below its steady-state level, given its roughly five-day half-life.

In that situation, simply "taking the next one and resuming as normal" isn't necessarily the safest move, particularly if you were mid-titration or on a higher maintenance dose. Restarting at your prior dose after a multi-week gap can mean your body responds to it more like a fresh, less-tolerant exposure than a routine continuation — which raises the odds of a harder GI reaction than you'd expect at a dose you'd previously tolerated fine. This is the scenario the label doesn't spell out a specific catch-up formula for, because it genuinely depends on individual factors: how long the gap was, what dose you were on, why the doses were missed, and how you tolerated titration the first time around.

This is the point where contacting your prescriber isn't just a cautious suggestion — it's the actual right next step, not a fallback for people who can't figure out the math themselves. Your prescriber may recommend resuming at your last dose as planned, or may recommend restarting at a lower step and re-titrating up more quickly than the original schedule, depending on the specifics. Either way, that's a clinical decision that benefits from someone who knows your history, not something to reconstruct from a label chart built around a single missed week.

If you're not sure whether your situation counts as "one missed dose" or "multiple," count backward to your last confirmed injection. If it's been more than roughly two weeks since your last dose, treat it as the multiple-dose scenario and reach out before injecting again, rather than assuming the standard 96-hour rule still cleanly applies.

Missing a weekly injection is common, and it's rarely about carelessness — it's almost always a scheduling or logistics problem, not a discipline problem. Understanding the usual causes makes it easier to prevent the next one, so it's worth naming them plainly rather than glossing over them.

Travel across time zones is one of the most frequent triggers. A weekly reminder tied to a specific time can quietly slip when you're crossing several zones over a few days, and by the time you notice, you're not sure if you've actually missed the window or just shifted it. Related to this: simply losing track of which day it is. Weekly medications are easy to lose the thread on precisely because a week is long enough that "was that Monday or Tuesday I took it" becomes a real question by the following week.

Running out of pen before a refill arrives is another common and entirely logistical cause — a pharmacy delay, an insurance prior-authorization holdup, or a shipping delay from a mail-order pharmacy can all leave you without medication on hand exactly when your dose is due, through no fault of your own. And occasionally it's mechanical: a pen that's been dropped, damaged, or stored improperly (left somewhere too hot, or accidentally frozen) that turns out to be unusable right when you go to use it, forcing an unplanned delay while you sort out a replacement.

None of these are reasons for self-judgment — they're just the practical realities of managing a weekly injectable medication over months or years. The more useful response is prevention: setting a reminder that accounts for your actual routine rather than a rigid clock time, requesting refills several days before you'll run out rather than the day of, checking pen condition when it arrives rather than assuming it's fine, and building in a buffer day or two of slack into your mental schedule so a single hectic day doesn't turn into a missed week.

Yes — and this is worth stating directly because it comes up constantly. Zepbound and Mounjaro are both tirzepatide, manufactured by Eli Lilly, differing only in their approved indications (Zepbound for chronic weight management, Mounjaro for type 2 diabetes) and, in some cases, packaging. They are not different formulations or different molecules with separately derived dosing science; they're the same active drug, dosed weekly, sold under two brand names for two different approved uses.

Because the missed-dose guidance in a drug's prescribing information is derived from the pharmacokinetics of the molecule itself — how quickly it's absorbed, how long it stays active, how its concentration behaves over a weekly cycle — Mounjaro's label carries the identical missed-dose language: take a missed dose within 4 days (96 hours), otherwise skip it and resume your regular schedule, and never let two doses fall closer than 3 days (72 hours) apart. If you've read guidance for one product's missed-dose rule, you've effectively read the other's too.

This matters practically for anyone who's switched between the two products — for example, someone who started on Mounjaro for diabetes and later moved to Zepbound, or vice versa, or someone whose insurance coverage shifted which brand name they're prescribed. The catch-up math doesn't change when the brand name on the pen does. It's also a useful sanity check if you're searching for guidance and land on a page about the "wrong" brand name by accident — the underlying rule you're reading still applies.